文献速递特殊人群用药药物相互作用肝肾功能剂量调整

特定人群中药物转运体丰度/功能改变与PBPK建模的临床意义:ITC视角

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective.
PubMed 文献 · Clin Pharmacol Ther · 2022-06-21

国际转运体联盟(ITC)白皮书综述了肾病、肝病、癌症及儿科、妊娠等特定人群中药物转运体表达与活性改变的研究进展及其临床意义。改变证据来自转运体蛋白组学定量数据、临床药代动力学及新兴生物标志物/药物基因组学数据,以及生理药动学(PBPK)建模与模拟。白皮书提示,对转运体介导的摄取/外排为其吸收、分布、消除主要途径或相关DDI风险的药物及其活性代谢物,需考虑这些人群中PK、PD与毒性改变的可能。

要点

  • 肾病、肝病、癌症及儿科、妊娠人群的转运体丰度/活性可能改变,需关注PK与毒性。
  • 转运体介导处置为主要途径的药物及其活性代谢物是重点评估对象。
  • PBPK建模与模拟可用于定量预测特定人群的转运体活性改变影响。

核心结论

  • 特定人群中转运体表达和/或功能改变可影响药物的PK、PD与毒性,应结合蛋白组学、临床PK及PBPK建模评估。
  • 对转运体介导的摄取/外排为吸收、分布、消除主要贡献途径或相关DDI风险的药物及活性代谢物,需考虑这些人群中PK、PD和毒性改变的可能。

研究设计与样本

  • 国际转运体联盟(ITC)白皮书,聚焦各类疾病(肾损伤、肝损伤、癌症)与特定人群(儿科、妊娠)中转运体表达和活性改变的研究进展与临床意义。
  • 所提出的转运体丰度和/或活性改变基于三类证据:特定人群与健康成人的定量转运体蛋白组学数据及相对丰度、临床PK及新兴转运体生物标志物和/或药物基因组学数据、PBPK建模与模拟。

主要发现

  • 膜转运体对药物PK、DDI、PD和毒性的作用已被广泛认识,但疾病人群或儿科、妊娠等特定人群中转运体表达和/或功能调控的认识仍在积累。
  • 白皮书总结了上述疾病与特定人群中转运体表达和活性改变研究的最新进展,重点关注临床意义。

临床怎么用

  • 对转运体介导处置为主要途径或存在相关DDI风险的药物及其活性代谢物,评估特定人群中PK、PD和毒性改变的可能性。
  • 可综合定量转运体蛋白组学、临床PK、生物标志物/药物基因组学数据与PBPK建模模拟,支持特定人群用药评估。

局限性

  • 白皮书指出,研究和定量预测这些人群中转运体活性调控效应仍存在当前挑战与知识空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of membrane transporters on pharmacokinetics (PKs), drug-drug interactions (DDIs), pharmacodynamics (PDs), and toxicity of drugs has been broadly recognized. However, our knowledge of modulation of transporter expression and/or function in the diseased patient population or specific populations, such as pediatrics or pregnancy, is still emerging. This white paper highlights recent advances in studying the changes in transporter expression and activity in various diseases (i.e., renal and hepatic impairment and cancer) and some specific populations (i.e., pediatrics and pregnancy) with the focus on clinical implications. Proposed alterations in transporter abundance and/or activity in diseased and specific populations are based on (i) quantitative transporter proteomic data and relative abundance in specific populations vs. healthy adults, (ii) clinical PKs, and emerging transporter biomarker and/or pharmacogenomic data, and (iii) physiologically-based pharmacokinetic modeling and simulation. The potential for altered PK, PD, and toxicity in these populations needs to be considered for drugs and their active metabolites in which transporter-mediated uptake/efflux is a major contributor to their absorption, distribution, and elimination pathways and/or associated DDI risk. In addition to best practices, this white paper discusses current challenges and knowledge gaps to study and quantitatively predict the effects of modulation in transporter activity in these populations, together with the perspectives from the International Transporter Consortium (ITC) on future directions.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chu X, Prasad B, Neuhoff S, et al. Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. Clin Pharmacol Ther. 2022. PMID: 35561140. doi:10.1002/cpt.2643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。